Boston Scientific Corporation, Hologic, Inc. and BD are Dominating the Global Needle Biopsy Market in 2020

Global Needle Biopsy Market is expected to grow with the CAGR of 4.2% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @

Global needle biopsy market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global needle biopsy market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in January 2021, Hologic, Inc. acquired SOMATEX Medical Technologies GmbH, a leader in biopsy site biomarkers, for USD 64 million. The acquisition funds Hologic Inc’s strategy to deliver a varied range of novel solutions for the treatment of breast cancer. Hologic, Inc. would be able to expand the breast cancer marker portfolio.

Boston Scientific Corporation is the dominating player in global needle biopsy market. The other key players existing in the needle biopsy market are Medax SRL, Cook, Hologic, Inc., ST. STONE MEDICAL DEVICES PVT. LTD., AprioMed AB, Amecath, Zamar Care, Cardinal Health, INRAD, Inc., BD, Möller Medical GmbH, HAKKO Corporation, ARGON MEDICAL, Merit Medical Systems, weLLgo Medical Products GmbH, Swastik Enterprise, Tsunami Medical Srl, Pajunk, B. Braun Melsungen AG among others.

Needle Biopsy MarketBoston Scientific Corporation:

Boston Scientific Corporation is headquartered in Massachusetts, U.S. and was founded in 1979. The company provides kits, reagents, instruments and services that help researchers explore questions about gene discovery, regulation and function. The company has several business segments such as medical surgical (MedSurg), rhythm and neuro and cardiovascular where medical surgical (MedSurge) is the dominating segment. The company has several products under categories including ablation access device, dilatation access device, sheath accessories, atherectomy systems balloons, dilation and extraction band, ligator baskets bronchial thermoplasty catheters, balloon catheters, diagnostic catheters, drainage catheters, guide catheters, support catheters, ureteral clips CRT-DCRT-PCTO, systems, deep brain stimulation systems, defibrillators (S-ICD, ICD), direct visualization systems, embolic protection, embolization, FFR & IVUS systems, forceps guidewires imaging systems, leads, needles, pacemakers, PCNL, plaque modification remote, patient monitoring, retrieval devices snares, sphincterotomes, spinal cord stimulator systems stents, coronary stents, gastrointestinal stents, pulmonary stents, ureteral stents and vascular thrombectomy systems in which needles is the market focused category.

For instance,

  • In February 2012, Boston Scientific Corporation announced the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle product launch. The aspiration needle is used to acquire tissue samples under Endoscopic Ultrasound (EUS) for cancer diagnosis. The product launch had resulted in the expansion of the endoscopy product portfolio and to choose the appropriate path for treatment of patients.

The company has wide presence across Americas, Asia-Pacific, Europe and Middle East and Africa. The company also has various subsidiary companies including Acurate Industria e Comercio Ltda. (Brazil), American Medical Systems Europe B.V. (Netherlands), Apama Medical, Inc. (U.S.), Augmenix, Inc. (U.S.), Biocompatibles International Limited (England) among others.

Hologic, Inc

Hologic, Inc. is headquartered in Massachusetts, U.S. and was founded in 1985. The company is focused on the development, manufacturing and supply of premium diagnostics products, medical imaging systems and surgical products, which focuses on women's health and well-being through early detection and treatment. The company operates its business via several business segments including diagnostics, breast health, GYN surgical and skeletal health in which breast health is the market focused segment. The company has several products under categories including breast health solutions, diagnostic solutions, GYN surgical solutions, skeletal solutions, safety data sheets and package inserts in which breast health solutions is the market focused category.

For instance,

  • In August 2020, Hologic, Inc introduced new updates about the Brevera Breast Biopsy System with CorLumina Imaging Technology. It’s the first system to integrate tissue biopsy with real-time imaging verifications. It would result in time management and enhanced storage. The updation would prove advantageous to the oncologists and for better identification and differentiation of target samples.

The company has presence across Asia-Pacific, Europe, Middle East and Africa and Americas. The company also has various subsidiaries including Mobidiag Oy (Finland), BioTheranostics, Inc (California), Cytyc (U.S.), Hologic Deutschland GmbH (Germany), SOMATEX Medical Technologies GmbH (Germany) among others.


BD is headquartered in New Jersey, U.S. and was incorporated in 1897. The company is engaged in the development, manufacturing and sale of wide range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates in three business segments including medical, life sciences and interventional in which medical segment is the focused segment. The company has many products under categories which are anesthesia delivery, biopsy, biosciences, biosurgery: sealant and hemostat solutions, cervical cancer screening, diabetes care, drug delivery systems, drainage, gastrointestinal care, hazardous drug safety, hernia repair and fixation, home care, infection therapy, interventional specialties, lab automation, microbiology solutions, molecular diagnostics, prostate health among others in which biopsy is the market focused category.

For instance,

  • In April 2021, BD announced that the company will be presenting in virtual investor healthcare conferences “The Bank of America Securities 2021 Virtual Healthcare Conference” and “The UBS Global Healthcare Virtual Conference”. This has helped the company in gaining more customers globally, and improved revenue for future market.

The company has presence across North America, South America, Europe, Asia-Pacific and Middle East and Africa. The company also has various subsidiaries including Accuri Cytometers, Inc. (Delaware), Accuri Cytometers (Europe), Ltd. (U.K.), Atto Bioscience, Inc. (Delaware), B-D (U.K.) Ltd. (U.K.) among others.